High prices make once-neglected ‘orphan’ drugs a booming business

Thirty years ago, Congress heard the plight of sick Americans. They are the victims of the failure of the pharmaceutical market - pharmaceutical companies ignore "orphans" as they believe that small group patients can lead to negligible sales

Pharmaceutical companies should pay drugs to treat insurance companies or the government as drugs to treat rare diseases defined as new drugs, especially orphan drugs, drugs affecting fewer than 200,000 patients in the United States You can set the price at a price that you can not do. Orphan drugs cost up to 400,000 dollars per year. The orphan drug business model may be regulated by more payer. When many generic drugs are introduced to the market, in most cases the cost of prescription drug purchase will be low for both insurance companies and patients. General pharmaceuticals have been shown to reduce medical expenses in various ways, including intensifying competition. This is most useful for lowering prices. https://www.fda.gov/ucm/groups/fdagov-public/documents/image/ucm129445.gif

The price of Orphan drug has also increased sharply. Recent studies have found that the median of orphan drugs has doubled every 5 years since 1983. The annual average inflation adjustment cost per patient for orphan drugs rose from $ 1,573 in 1983-1984 to $ 100,555 in 2010-2014 and increased by 64 times in inflation adjustments. 30 in the period from 2012 to 2014, 45 kinds of price orphan drugs repeat the average of 30% 0.31 manufacturers, existing products and indications as well as orphan drugs for all previous indications Roses with approval of indications. According to regulations, manufacturers can divide the disease into several subspecies diseases, each of which is a rare illness. About a quarter

Manufacturers reuse old drugs originally developed for non-orphaned diseases as therapeutic drugs for orphan diseases and raise the drug price for all indications. Whether for older or new indications, due to an isolated indication at 0.35 of over 70 kinds of orphan drugs originally approved for non-orphan diseases, manufacturers can raise the price of pharmaceuticals As approved Orphan drug market exclusivity for seven years 0.34 Old medicine eg Hewlett-Packard ActharGel (adrenocorticotropic hormone) To obtain orphan drugs approved for the treatment of infantile spasm, Prices have increased more than $, 20,000 0.36 since the 1950s, adrenocorticotropic hormone has been used to treat several other diseases including multiple Sex sclerosis, arthritis and inflammatory eyes The use of it is used to treat infantile spasm outside the label. Normally, the price of the vial before obtaining orphan drug approval is $ 1,650.